Drug Trials Snapshots: BRIUMVI (ublituximab-xiiy)

BRIUMVI is a monoclonal antibody that is used to treat relapsing forms of multiple sclerosis (MS) including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. In relapsing forms of MS (RMS), patients have episodes of worsening function (relapses) followed by recovery periods. Patients can also experience an increase in the underlying disability, particularly as the disease progresses. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-briumvi